A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer ; volume:6 ; number:1 ; day:27 ; month:2 ; year:2018 ; pages:1-14 ; date:12.2018
Journal for ImmunoTherapy of Cancer ; 6, Heft 1 (27.2.2018), 1-14, 12.2018
- Creator
-
Engel-Riedel, Walburga
- Contributor
-
Lowe, Jamie
Mattson, Paulette
Richard Trout, J.
Huhn, Richard D.
Gargano, Michele
Patchen, Myra L.
Walsh, Richard
Trinh, My My
Dupuis, Mariève
Schneller, Folker
SpringerLink (Online service)
- DOI
-
10.1186/s40425-018-0324-z
- URN
-
urn:nbn:de:1111-20180424610
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Engel-Riedel, Walburga
- Lowe, Jamie
- Mattson, Paulette
- Richard Trout, J.
- Huhn, Richard D.
- Gargano, Michele
- Patchen, Myra L.
- Walsh, Richard
- Trinh, My My
- Dupuis, Mariève
- Schneller, Folker
- SpringerLink (Online service)
Other Objects (12)
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: results of the NEPTUN study
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: final results of the NEPTUN study
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: results of the NEPTUN study
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: final results of the NEPTUN study
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Atezolizumab (NSCLC; Kombination mit Bevacizumab, Carboplatin und Paclitaxel) : Nutzenbewertung gemäß § 35a SGB V
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: results of the NEPTUN study
A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients
First‐line nab‐paclitaxel plus carboplatin for patients with advanced non‐small cell lung cancer: final results of the NEPTUN study
[18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study
Complete Response of Recurrent Small Cell Carcinoma of the Uterine Cervix to Paclitaxel, Carboplatin, and Bevacizumab Combination Therapy
Paclitaxel und Paclitaxel-Carboplatin beim fortgeschrittenen nichtkleinzelligen Bronchialkarzinom : Auswertung klinischer Phase-II-Studien
To assess the role of addition of bevacizumab therapy to carboplatin and paclitaxel as frontline treatment of epithelial ovarian cancer
Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France